secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0001140361-25-009729
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Opus Genetics reports preliminary FY 2024 net loss of $56.8M, cash burn $25.6M
------------------------------------------------------------------------------

- Net loss for FY 2024 expected to be approximately $56.8 million.
- Net cash used in operating activities for FY 2024 approximately $25.6 million.
- Cash and cash equivalents balance as of Dec 31, 2024 approximately $30.3 million.
- All figures are preliminary, unaudited and subject to change upon finalization of audited financials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125009729/0001140361-25-009729-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125009729/ef20045937_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-009729

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer